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Part 2 of this paper deals with the techniques for drug delivery of topical and injectable local anaesthetics. The various routes
of local anaesthetic delivery (epidural, peripheral, wound catheters, intra-nasal, intra-vesical, intra-articular, intra-osseous) are
explored. To enhance transdermal local anaesthetic permeation, additional methods to the use of an eutectic mixture of local
anaesthetics and the use of controlled heat can be used. These methods include iontophoresis, electroporation, sonophoresis, and
magnetophoresis. The potential clinical uses of topical local anaesthetics are elucidated. Iontophoresis, the active transportation
of a drug into the skin using a constant low-voltage direct current is discussed. It is desirable to prolong local anaesthetic blockade
by extending its sensory component only. The optimal release and safety of the encapsulated local anaesthetic agents still need to
be determined. The use of diﬀerent delivery systems should provide the clinician with both an extended range and choice in the
degree of prolongation of action of each agent.
1.Introduction
A drug delivery system should have minimal tissue reaction,
a reliable drug release proﬁle, and well-deﬁned degradation
rate for biodegradable carrier until all nontoxic products are
excreted[1].Forlocalanaesthetics(LAs),thedevelopmentof
new eﬀective delivery systems intends to suitably modulate
the release rate of these drugs, extend their anaesthetic effect,
and enhance their localisation; this reduces problems of sys-
temic toxicity. Part 2 of this paper deals with the innovations
pertaining to formulations, and techniques for drug delivery
of topical and injectable local anaesthetics.
2.Routes of Local AnaestheticDelivery
2.1. Epidural. Patient controlled epidural analgesia (PCEA)
allows patients to self-administer drug doses according to
their analgesic needs. This route relies on a staﬀ-program-
med pump and skilled and qualiﬁed members of the hospital
staﬀ for administration. Both local anaesthetics and opioids
are agents for epidural analgesia. The use of epidural lo-
cal anaesthetics is associated with a higher incidence of
hypotension, motor block, and urinary retention, compared
with use of opioids [2]. However, in a recent meta-analysis,
only a continuous infusion of epidural local anaesthetics was
superior to intravenous opioids in improving pain control
and reducing adverse eﬀects [3].
2.2. Peripheral. Patient-controlled regional analgesia (PCRA)
encompasses a variety of techniques that provide eﬀective
postoperative pain relief without systemic exposure to
opioids. Using PCRA, patients initiate the delivery of small
doses of local anaesthetics (ropivacaine, bupivacaine) via an
indwelling catheter that can be placed in diﬀerent regions of
the body depending upon the type of surgery. In some cases,
a combination of local anaesthetic and opioid is adminis-
tered. Infusions are controlled either by a staﬀ-programmed
electronic pump (Figure 1) or by a disposable elastomeric
pump [3]. An elastomeric pump is a device that has a dis-
tensible bulb inside a protective bulb with a built-in ﬁlling
port, delivery tube, and an antibacterial ﬁlter. Antibacterial
ﬁlters are recommended with blocks involving a nerve plexus
(and in neuraxial blocks). Analgesia can be delivered directly
into a surgical incision (incisional PCRA), the intra-articular
tissue (IA PCRA), or the perineural site (perineural PCRA)
(Figure 2)[ 2].
2.3. Wound Catheters. The insertion of wound catheters al-
lows for continuous infusions of local anaesthetics into the
surgical wound at the end of the procedure (Figure 3).2 Anesthesiology Research and Practice
Figure 1: Pharmacia Deltec CADD Ambulatory Infusion Pump.
Figure 2:Patient-controlledperineuralanalgesiaviainfraclavicular
brachial plexus catheter.
Continuous wound catheters can confer several beneﬁts, in-
cluding improved analgesia, reduced opioid use and adverse
eﬀects, increased patient satisfaction, and reduced hospital
stay [4].
The use of continuous wound catheters consistently re-
duces the need for opioids (both rescue and total dose). Pa-
tients have consistently rated postoperative nausea and vom-
iting (PONV) as a primary concern after surgery [5, 6]. The
reduced need for opioids (though an infrequently measured
result in Randomised Controlled Trials) might contribute to
increased patient satisfaction [4]. Reduced length of hospital
stay has been associated with continuous wound catheters,
especially in the cardiothoracic and orthopaedic surgery
subgroups [4]. Meta-analysis suggested the potential saving
of one day of hospital stay [4]. Incidences of technical failure
and local anaesthetic toxicity from wound catheters are low.
Several reports have raised potential concern about wound
infections from the presence of a catheter [7]. However, re-
ported wound infection rates were found to be similar
between active (0.7%) and control groups (1.2%) [4].
2.4. Intranasal Route. The nasal mucosa acts as an anatom-
ical obstacle hard to get over, except for compounds with
Figure 3: Elastomeric pump for a wound catheter.
low molecular weight or highly lipophilic compounds. For
the manipulation of nasal fractures, lignocaine and cocaine
have been used in topical local anaesthesia in the form of
a spray, paste, or on cotton wool and pledgets; this appears
to be a safe and eﬀective alternative to general anaesthesia.
A systematic review has found no signiﬁcant diﬀerences
between local anaesthesia and general anaesthesia as regards
pain,cosmesisornasalpatencyafternasalfracturemanipula-
tion performed under topical local anaesthesia [8]. A recent
Cochrane review showed that nasopharyngeal topical local
anaesthetic or vasoconstrictor preparations prior to the use
of a ﬁbre-optic nasal endoscope did not demonstrate any
advantages in using a topical treatment prior to endoscopy
[9]. In contrast, the very lipophilic opioids, such as fentanyl
are rapidly absorbed via intranasal administration (with a
bioavailability close to 90% for fentanyl) and are used for the
treatment of breakthrough pain [10].
2.5. Intravesical (Bladder) Route. T h et r a n s p o r to fl o c a la n -
aesthetics through the urothelium into deeper layers of the
bladder has been signiﬁcantly enhanced by electromotive
drug administration (Figure 4)[ 11]. It is a cost-eﬀective way
to deliver lignocaine with greatly improved penetration rate
into the bladder wall [12]. Vehicles such as electromotive
drugadministration,newinsitudeliverysystems,andbioad-
hesive liposomes make it possible to extend intravesical ther-
apy and drug administration to many bladder diseases [11].
2.6. Intra-Articular (IA) Route. For microspheres destined
for intra-articular delivery, the following properties have
been identiﬁed as important, namely, size (within the range
of 4-5µm in diameter), resistance to in vivo degradation,
minimal leakage of drug, and biocompatibility [13]. Pro-
longingtheintra-articulardrugresidencetimeofLAsmaybe
met by formulating microspheres that have been rationally
designed to optimise uptake by the synovium [13]. However,
the causes of 23 cases of postarthroscopic glenohumeral
chondrolysis were recently analysed. Several common factors
were found, but no single mechanism was shown. MultipleAnesthesiology Research and Practice 3
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Figure 4:Thestructureoftheurinarybladderwallandurothelium.
factors seemed to be implicated. The use of intra-articular
local anaesthetics is probably not advisable until the role of
local anaesthetics in this regard has been clariﬁed, as chon-
drolysis has been the subject of many lawsuits [14].
2.7. Intra-Osseous Route. Computer-controlled local anaes-
thetic delivery devices (C-CLAD) and systems for intra-
osseous injection are important additions to the dental an-
aesthesia armamentarium [15]. C-CLAD using slow infu-
sion rates can signiﬁcantly reduce the discomfort of local
anaesthetic infusions, especially in palatal tissues; C-CLAD
facilitates palatal approaches to pulpal nerve block. It should
ﬁnd special use in cosmetic dentistry, periodontal therapy,
and paediatric dentistry [15].
3. TransdermalRoute of Local Anaesthetic
Drug Delivery
Transdermaldrugdeliveryisoneofthemostpatient-compli-
ant routes of drug administration. However, the stratum
corneum, the outer most layer of the skin resists the penetra-
tion of drugs across the skin (Figure 5). Hydrophilic, ionised,
and macromolecular substances are poorly permeable across
the skin [16]. To enhance drug permeation in a passive
manner, transdermal drugs should be lipophilic and should
ideally have a molecular weight less than 500 Daltons [17].
Alternatively, energy-dependent active measures can be used
to enhance drug delivery across the skin. These include
physical permeabilisation of skin or by driving the drug
molecule across the skin. In addition to the use of an eutectic
mixture of local anaesthetics, and the use of controlled heat,
other methods such as iontophoresis, electroporation, sono-
phoresis, and magnetophoresis can be used [16].
3.1. Magnetophoresis. Magnetophoresis is a method of en-
hancement of drug permeation across the biological barriers
by the application of a magnetic ﬁeld (Figure 6). The pre-
dominant mechanism responsible for magnetically mediated
drug permeation enhancement is known as “magnetokine-
sis” [17]. The octanol/water partition coeﬃcient of drugs
increases when exposed to the magnetic ﬁeld [17]. Magne-
tophoretic patch systems deliver drugs at a higher rate than
nonmagnetic patch systems. In the rat model, the dermal
bioavailability (Area Under the Curve 0–6 hours) from the
magnetophoretic patch system was signiﬁcantly higher com-
pared to a non-magnetic control patch [17].
3.2. Sonophoresis/Phonophoresis. The use of ultrasound for
the delivery of drugs to, or through, the skin is commonly
known as sonophoresis or phonophoresis (Figure 7). The
frequencyoftheultrasoundwavecorrespondstothenumber
of times that the transducer tip is displaced per second
of application time. High-frequency sonophoresis includes
frequencies in the range of 0.7–16MHz (most commonly 1–
3MHz) [18]. Low-frequency sonophoresis includes frequen-
ciesintherangeof20–100kHzandallowstransdermaldeliv-
ery of both hydrophilic and high-molecular mass permeants
at therapeutic levels [19].
The main contributor responsible for skin permeability
enhancement by sonophoresis is acoustic cavitation. This
causes the formation of acoustic microjets on the surface of
the skin in a nonuniform manner [19]. When surfactant is
included in the treatment of skin with low-frequency sono-
phoresis, a strong synergistic enhancement in skin permea-
bilityoccurs,allowingdeliveryofhydrophilicpermeants.Ad-
ditionally, low-frequency sonophoresis-mediated transder-
mal delivery can be used to deliver macromolecules, includ-
ingliposomesandnanoparticles[19].Thistechnologyiscur-
rently approved for use by the Federal Drug Administration
(FDA) for local anaesthetics. In volunteers, a transducer has
been used to administer an anaesthetic drug transdermally.
When 0.5MHz ultrasound in phonophoresis used for con-
duction anaesthesia with lignocaine hydrochloride, it was
found to be more eﬀective than the 1MHz widely used in
clinical situations (Figure 7)[ 20].
3.3. Microporation Technologies. Skin microporation may be
considered a minimally invasive technology that can be
broadly divided into microneedle technology, thermal mi-
croporation, and laser ablation [21]. To improve the rate and
extent of transdermal lignocaine across porcine ear skin, the
application of novel laser microporation technology (Pain-
less Laser Epidermal System) has been used to create well-
deﬁned conduits in the skin [22].
3.4. Electroporation. Electroporation is the application of
short high voltage pulses that result in formation of transient
aqueous pathways for diﬀusion of molecules across the skin
[16]. In case of electroporation, the electrical pulses are ap-
plied only for fraction of a second; the interval between sub-
sequent pulses allows the skin to depolarise [16]. Therefore,
polarisation of skin does not interfere with the current ﬂow
or drug diﬀusion. In the porcine epidermis, the transport of
lignocaine hydrochloride in case of low voltage electropulsa-
tion was found to be 8-fold more than the control [16]. The
amountoflignocainehydrochloridepresentintheepidermis
was found to be 2-fold higher as well.4 Anesthesiology Research and Practice
Paracellular route
Transcellular route
Transappendageal route
Epidermis
Hair shaft
Dermis
Subcutaneous fat
Sweat duct
Fat globules
Blood vessels
Figure 5: Transdermal routes of absorption of local anaesthetics.
Figure 6: Magnetophoresis.
Electrokinesis (electrophoresis and or electro-osmosis)
and permeabilisation of membranes are responsible for en-
hanced transdermal drug transport by low voltage electro-
poration. The total duration of electrical current application
during 20 minutes of low voltage electroporation is only one
minute. Low voltage electroporation enhances drug perme-
ation relatively more eﬃciently than constant direct current
iontophoresis [16].
3.5. Eutectic Patches. A new topical local anaesthetic eutectic
patch consisting of a mixture of lignocaine 70mg and tetra-
caine70mg(SyneraintheUnitedStates,RapydaninEurope)
has been developed [23]. This patch has an integrated heat-
ing element intended to enhance the ﬂux of the tetracaine
and lignocaine leading to more rapid and eﬀective delivery
of the local anaesthetics to the target area. The patch starts
heating once removed from the pouch and exposed to at-
mospheric oxygen; it may increase skin temperature by up
to 5◦C[ 23].
To study the use of lignocaine/tetracaine-medicated plas-
ters in patients undergoing minor dermatological or vascular
access procedures, patients were randomised in a double-
blind clinical trial [24]. Patient-reported median pain scores
withtheuseoflignocaine/tetracaine-medicatedplasterswere
Sonophoresis
Return
electrode
Figure 7: Sonophoresis—an ultrasonic skin permeation device.
found to be signiﬁcantly lower than those with an identical
plaster-containing placebo [24].
3.6. Clinical. With the use of topical local anaesthetics for
dermal laceration repair, a meta-analysis reviewed 22 trials
with more than 3000 randomised patients; it concluded that
topical tetracaine, bupivacaine, and lignocaine had an equiv-
alent or superior analgesic eﬃcacy to the intradermal inﬁl-
tration of cocaine-containing anaesthetics. The topical prep-
arations proved less expensive and were safer [23, 25]. In
anotherrecentmeta-analysisof25trialswithmorethan2000
subjects, three topical anaesthetics, (tetracaine, liposome-
encapsulated tetracaine, and liposome-encapsulated ligno-
caine) were found to be equally eﬃcacious [26]. Tetracaine
had the added advantage of a longer duration and was re-
portednottocausemethemoglobinemia[27].Anotherstudy
has demonstrated that the lignocaine/tetracaine patch pro-
vided better local anaesthesia than the control at all applica-
tion times under 60 minutes [28].
Potential uses of topical anaesthetics include the follow-
ing: for gaining pain-free vascular access; for skin or punchAnesthesiology Research and Practice 5
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Figure 8: Iontophoresis. Components of an anodal iontophoretic
device are a current source; a current control device; anode (donor)
reservoir system (with a positively charged drug/ion in solution);
cathode reservoir system (on a diﬀerent skin site). With an electric
current,allcationsmoveawayfromtheanodeandintotheskin,and
negatively charged ions move from the body into donor reservoir.
biopsies; for bone marrow aspiration; for treatment of pos-
therpetic neuralgia; for immunisation; for myofascial pain
due to trigger points; for nerve entrapment such as carpal
tunnel syndrome; for regional block placement; and for
dermal procedures requiring laser treatment.
4. Iontophoresis
Iontophoresis involves the active transportation of a drug
into the skin using a constant low-voltage direct current.
Ions migrate between electrodes of opposite charges, pro-
moting ion transport through the skin (Figure 8)[ 29]. A
direct electrical current facilitates the dermal penetration of
positively charged lignocaine molecules when placed under
a positive electrode for local anaesthesia. Physicochemical
properties, such as good aqueous solubility, and the presence
ofchargedgroupsthatrenderpeptidesandproteins“diﬃcult
to deliver” by other approaches, are ideal for iontophoresis
[30] The amount of drug delivered via iontophoresis is de-
pendent on the current and the duration of delivery. The
control aﬀorded by constant current iontophoresis over
transport rates means that peptide/protein delivery kinetics
could mimic endogenous secretion proﬁles [30]. Moreover,
complex input kinetics can be used to optimise and individ-
ualise therapy.
Iontophoresis has been known to cause skin irritation at
higher current densities or upon longer application [16, 31,
32]. Moreover, when direct current electric ﬁeld is applied
overlongerdurations,anelectrochemicalpolarisationoccurs
in the skin which decreases the magnitude of current ﬂow
through the skin [16]. This in turn could aﬀect the amount
of drug ions driven across the skin.
Small, portable iontophoresis devices have been devel-
oped.Dermalanaesthesiacanbeachievedfairlyrapidlyusing
lignocaine iontophoresis without needles [29]. Adrenaline
added to the lignocaine solution enhances the eﬀect and
durationoflocalanaesthesiaduringiontophoresis;thisisdue
tothelocalvasoconstrictioninhibitinglignocaineabsorption
into the systemic circulation.
Delivery can be hastened by using ultrasound. In a Ran-
domisedControlledTrial,ultrasoundpretreatmentplustwo-
minute low-voltage iontophoresis provided better skin an-
aesthesia than sham-ultrasound plus two-minute low-volt-
age iontophoresis, and similar to standard, 10-minute high-
voltage iontophoresis [33]. Lignocaine HCl 10%/Adrenaline
0.1% topical iontophoretic patch (LidoSite) is the ﬁrst FDA-
approved preﬁlled active anaesthetic patch. In volunteers, it
was found that 2% lidocaine could be delivered up to 5mm
below the surface of the skin when the drug compound
containedadrenaline,andwhenpassivedeliveryoccurredfor
at least 50 minutes after the active delivery has terminated
[34].
5.Future
It is desirable to acquire the ability to prolong local anaes-
thetic blockade and, if possible, extend only its sensory com-
ponent. This paper portrayed the innovative techniques for
the drug delivery of topical and injectable local anaesthetics.
However, the optimal release and safety of the encapsulated
LA agents still need to be determined. Using encapsulation
to avoid systemic toxicity, the nonconventional local anaes-
thetics (tetrodotoxin, saxitoxin) show promising eﬃcacy [1].
Recently, lignocaine-coated microneedles have been devel-
oped for rapid, safe, and prolonged local analgesic action
[35]. These delivery systems should provide the clinician
with both an extended range and a choice in the degree of
prolongation of action of each agent [36].
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